Navigation Links
Research offers promising new approach to treatment of lung cancer
Date:5/22/2013

CORVALLIS, Ore. Researchers have developed a new drug delivery system that allows inhalation of chemotherapeutic drugs to help treat lung cancer, and in laboratory and animal tests it appears to reduce the systemic damage done to other organs while significantly improving the treatment of lung tumors.

This advance in nanomedicine combines the extraordinarily small size of nanoparticles, existing cancer drugs, and small interfering RNA (siRNA) that shut down the ability of cancer cells to resist attack.

The combination of these forces resulted in the virtual disappearance of lung tumors in experimental animals.

Lung cancer is the leading cancer killer in both men and women. Despite advances in surgery, chemotherapy still plays a major role in its treatment. However, that treatment is constrained by the toxic effects of some drugs needed to combat it and the difficulty of actually getting those drugs into the lungs.

The findings were made by Oleh Taratula at Oregon State University and Tamara Minko and O. Garbuzenko at Rutgers University and the Cancer Institute of New Jersey. They were just published in the Journal of Controlled Release.

"Lung cancer damage is usually not localized, which makes chemotherapy an important part of treatment," said Taratula, an assistant professor in the OSU College of Pharmacy and co-author on this study. "However, the drugs used are toxic and can cause organ damage and severe side effects if given conventionally through intravenous administration.

"A drug delivery system that can be inhaled is a much more efficient approach, targeting just the cancer cells as much as possible," he said. "Other chemotherapeutic approaches only tend to suppress tumors, but this system appears to eliminate it."

A patent is being applied for on the technology, and more testing will be necessary before it is ready for human clinical trials, the researchers said.

The foundation of the new system is a "nanostructured lipid nanocarrier," tiny particles much smaller than a speck of dust that are easily inhaled and also readily attach to cancer cells. This carrier system delivers the anticancer drug. However, it also brings siRNA that makes the cancer cell more vulnerable.

Cancer cells often have two forms of resistance to drugs "pump" resistance that tends to pump the drug out of cells, and "nonpump" resistance that helps keep the cell from dying. The siRNA used in this system helps to eliminate both those forms of resistance, and leaves the cancer cell vulnerable to the drug being used to kill it.

By being inhaled, this system also avoids degradation of the chemotherapeutic agents that occurs when they are injected, researchers said. They arrive in more intact form, ready to do their job on lung cancer cells, while minimizing any side effects.

In more conventional chemotherapy for lung cancer, the drugs tend to accumulate in the liver, kidney and spleen, with much less of the drugs ever making it to the lungs. In this study, the amount of the drug delivered to the lungs rose to 83 percent with the inhalation approach, versus 23 percent with injection.


'/>"/>

Contact: Oleh Taratula
oleh.taratula@oregonstate.edu
541-737-3424
Oregon State University
Source:Eurekalert

Related medicine news :

1. Insulin Pump Therapy Provides Better Glycemic Control Among Type 1 Diabetics, According to Kantar Health Research
2. Protease Leads Feed Enzyme Market as Compared to Phytase & NSP Says New Research Report at ReportsnReports.com
3. Researchers find genetic risk factor for pulmonary fibrosis
4. Researchers find genetic tie to improved survival time for pulmonary fibrosis
5. Research at the cutting edge of knowledge
6. Fertility Clinics in Australia Industry Market Research Report Now Available from IBISWorld
7. Iowa VP for Research addresses next-generation supercomputers at congressional hearing
8. JPIDS: Releases consensus statement on research definitions for drug-resistant TB in children
9. Adeptia Featured in Recent 451 Research Impact Report
10. NYUs Movshon receives Lashley Award for his research on the neuroscience of vision
11. New multi-million dollar research center aims to solve the mystery of premature birth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2017)... ... April 27, 2017 , ... Healthcare companies are trying to ... rapidly reject an outdated healthcare executive resume. , “If you’re a healthcare executive open ... resume and wondering if it’s as ready as you are for a new job ...
(Date:4/27/2017)... (PRWEB) , ... April 27, 2017 , ... ... named the 2017 North American CAREGiverSM of the Year for her extraordinary compassion ... one of its 60,000 North American professional caregivers for the prestigious award each ...
(Date:4/27/2017)... ... 27, 2017 , ... Offering the purest product of its kind, Swissx Labs ... more potent than the market has seen before. Swissx uses proprietary strains of hemp ... patented chromatography process for extraction, to produce its CBD oil--maximizing its benefits for health ...
(Date:4/26/2017)... ... April 26, 2017 , ... Jump Technologies, Inc., ... announced it has completed a round of funding to accelerate its growth strategies. ... Black Granite Capital is a growth equity firm focused on investments in healthcare ...
(Date:4/26/2017)... , ... April 26, 2017 ... ... is thrilled to announce the ATA 2017 President’s Awards recipients, comprised of ... demonstrated superior healthcare delivery. , The ATA 2017 President’s Awards recognize ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017  Zimmer Biomet Holdings, Inc. (NYSE ... today announced that it will be participating in the ... the InterContinental Hotel in Boston, Massachusetts ... present at 11:20 a.m. Eastern Time. A ... Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com .  ...
(Date:4/20/2017)... 2017   ZappRx, Inc ., a digital health company ... today announced it closed $25 million in Series B funding ... based in Seattle that is part ... The Series B round included participation from SR One ... GV (formerly Google Ventures). As part of the ...
(Date:4/20/2017)... 20, 2017 Research and Markets has ... Manufacturing Services Market Analysis By Service (Manufacturing, Research), By Country, ... - 2025" report to their offering. ... The Latin American pharmaceutical contract manufacturing ... 2025 Low drug registration cost in Latin American ...
Breaking Medicine Technology: